Bayer eyes wider Nubeqa use on new prostate cancer trial data (updated)
17/07/2024 07:08
(Rewrites throughout)
By Ludwig Burger
FRANKFURT, July 17 (Reuters) - Bayer BAYGn.DE said on
Wednesday its Nubeqa drug was shown to slow the progression of a
certain type of prostate cancer in a late-stage trial,
underpinning growth prospects for one of the German drugmaker's
key pharmaceutical products.
Bayer is developing Nubeqa, also known as darolutamide,
jointly with Finland's Orion ORNBV.HE . The drug is already
approved in other prostate cancer treatment settings.
Bayer said in a statement that Nubeqa, when combined with
androgen deprivation therapy, significantly prolonged
progression-free survival when compared with androgen
deprivation therapy alone in a phase III trail.
Trial participants suffered from a type of metastatic
prostate cancer that responds to hormone therapy.
Details of the trial would be presented at an as yet
undisclosed medical conference, Bayer said, adding that it plans
to seek regulatory approval for wider use of the drug.
(Reporting by Ludwig Burger, Editing by Rachel More)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))